CLINICAL SIGNIFICANCE OF BCL–2 GENE EXPRESSION FOR THE PROGNOSIS AND MONITORING OF ACUTE GRAFT–VERSUS–HOST–DISEASE (AGVHD) IN ALLO–HSCT

Abstract. Our general purpose was to investigate bcl–2 gene expression in patients treated by allogeneic unrelated haematopoietic stem cells transplantation (aUHSCT) for the evaluation of aGvHD. Total RNA from the leukocytes of 19 oncohaematological patients was collected before starting the conditi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	M. I. Zaraiski
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2014
Materias:	transplantation bcl–2 gene acute graft-versus-host-disease Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/8236ac54e2c74d2a8aaf769eb606f73b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8236ac54e2c74d2a8aaf769eb606f73b
record_format	dspace
spelling	oai:doaj.org-article:8236ac54e2c74d2a8aaf769eb606f73b2021-11-18T08:03:41ZCLINICAL SIGNIFICANCE OF BCL–2 GENE EXPRESSION FOR THE PROGNOSIS AND MONITORING OF ACUTE GRAFT–VERSUS–HOST–DISEASE (AGVHD) IN ALLO–HSCT1563-06252313-741X10.15789/1563-0625-2005-4-381-384https://doaj.org/article/8236ac54e2c74d2a8aaf769eb606f73b2014-07-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/488https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XAbstract. Our general purpose was to investigate bcl–2 gene expression in patients treated by allogeneic unrelated haematopoietic stem cells transplantation (aUHSCT) for the evaluation of aGvHD. Total RNA from the leukocytes of 19 oncohaematological patients was collected before starting the conditioning regimen (D–T), at the day of hematological recovery (D–R) and at the D+30. An original RT–PCR protocol was developed, by quantifying the signals from the target genes, as compared to beta–actin as a reference gene. We have shown that the levels of bcl–2 expression in aGVHD patients were higher, as compared to aGVHD–free patients at D–T (Р=0,011), like as D–R (Р=0,012) time–points. The patients at the D–R and D+30 were divided into two groups, either with or without clinical signs of aGvHD at these observation terms (resp., groups I and II). At D–R point, bcl–2 expression in the 1st group was two–fold higher, than in the patients of second group (P=0,05). By the contrary, bcl–2 expression by the D+30 in group I was two–fold lower, as compared to the patients of second group (Р=0,016). Thus, we suggest the monitoring of bcl–2 expression to be of certain clinical significance. This criterion could be used as additional approach to prediction of aGVHD development and adjustment of immunosuppressive therapy. We also suppose that the role of the bcl–2 in the pathogenesis of aGvHD should be analyzed in more details. (Med. Immunol., 2005, vol.7, № 4, pp. 381–384)M. I. ZaraiskiSPb RAACIarticletransplantationbcl–2 geneacute graft-versus-host-diseaseImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 7, Iss 4, Pp 381-384 (2014)
institution	DOAJ
collection	DOAJ
language	RU
topic	transplantation bcl–2 gene acute graft-versus-host-disease Immunologic diseases. Allergy RC581-607
spellingShingle	transplantation bcl–2 gene acute graft-versus-host-disease Immunologic diseases. Allergy RC581-607 M. I. Zaraiski CLINICAL SIGNIFICANCE OF BCL–2 GENE EXPRESSION FOR THE PROGNOSIS AND MONITORING OF ACUTE GRAFT–VERSUS–HOST–DISEASE (AGVHD) IN ALLO–HSCT
description	Abstract. Our general purpose was to investigate bcl–2 gene expression in patients treated by allogeneic unrelated haematopoietic stem cells transplantation (aUHSCT) for the evaluation of aGvHD. Total RNA from the leukocytes of 19 oncohaematological patients was collected before starting the conditioning regimen (D–T), at the day of hematological recovery (D–R) and at the D+30. An original RT–PCR protocol was developed, by quantifying the signals from the target genes, as compared to beta–actin as a reference gene. We have shown that the levels of bcl–2 expression in aGVHD patients were higher, as compared to aGVHD–free patients at D–T (Р=0,011), like as D–R (Р=0,012) time–points. The patients at the D–R and D+30 were divided into two groups, either with or without clinical signs of aGvHD at these observation terms (resp., groups I and II). At D–R point, bcl–2 expression in the 1st group was two–fold higher, than in the patients of second group (P=0,05). By the contrary, bcl–2 expression by the D+30 in group I was two–fold lower, as compared to the patients of second group (Р=0,016). Thus, we suggest the monitoring of bcl–2 expression to be of certain clinical significance. This criterion could be used as additional approach to prediction of aGVHD development and adjustment of immunosuppressive therapy. We also suppose that the role of the bcl–2 in the pathogenesis of aGvHD should be analyzed in more details. (Med. Immunol., 2005, vol.7, № 4, pp. 381–384)
format	article
author	M. I. Zaraiski
author_facet	M. I. Zaraiski
author_sort	M. I. Zaraiski
title	CLINICAL SIGNIFICANCE OF BCL–2 GENE EXPRESSION FOR THE PROGNOSIS AND MONITORING OF ACUTE GRAFT–VERSUS–HOST–DISEASE (AGVHD) IN ALLO–HSCT
title_short	CLINICAL SIGNIFICANCE OF BCL–2 GENE EXPRESSION FOR THE PROGNOSIS AND MONITORING OF ACUTE GRAFT–VERSUS–HOST–DISEASE (AGVHD) IN ALLO–HSCT
title_full	CLINICAL SIGNIFICANCE OF BCL–2 GENE EXPRESSION FOR THE PROGNOSIS AND MONITORING OF ACUTE GRAFT–VERSUS–HOST–DISEASE (AGVHD) IN ALLO–HSCT
title_fullStr	CLINICAL SIGNIFICANCE OF BCL–2 GENE EXPRESSION FOR THE PROGNOSIS AND MONITORING OF ACUTE GRAFT–VERSUS–HOST–DISEASE (AGVHD) IN ALLO–HSCT
title_full_unstemmed	CLINICAL SIGNIFICANCE OF BCL–2 GENE EXPRESSION FOR THE PROGNOSIS AND MONITORING OF ACUTE GRAFT–VERSUS–HOST–DISEASE (AGVHD) IN ALLO–HSCT
title_sort	clinical significance of bcl–2 gene expression for the prognosis and monitoring of acute graft–versus–host–disease (agvhd) in allo–hsct
publisher	SPb RAACI
publishDate	2014
url	https://doaj.org/article/8236ac54e2c74d2a8aaf769eb606f73b
work_keys_str_mv	AT mizaraiski clinicalsignificanceofbcl2geneexpressionfortheprognosisandmonitoringofacutegraftversushostdiseaseagvhdinallohsct
_version_	1718422488734498816

CLINICAL SIGNIFICANCE OF BCL–2 GENE EXPRESSION FOR THE PROGNOSIS AND MONITORING OF ACUTE GRAFT–VERSUS–HOST–DISEASE (AGVHD) IN ALLO–HSCT

Ejemplares similares